BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9712490)

  • 21. Blood stem cell procurement: donor safety issues.
    Anderlini P; Przepiorka D; Körbling M; Champlin R
    Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S35-9. PubMed ID: 9712491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of long-term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts.
    Theilgaard-Mönch K; Raaschou-Jensen K; Andersen H; Russell CA; Vindeløv L; Jacobsen N; Dickmeiss E
    Bone Marrow Transplant; 1999 Feb; 23(3):243-9. PubMed ID: 10084255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of free hepatitis C virus core antigen by enzyme-linked immunosorbent assay is not suitable for screening of granulocyte colony-stimulating factor-mobilized hematopoietic progenitor donors.
    Lozano ML; Candela MJ; Cano H; Zuazu I; Vicente V
    Transfusion; 2004 Dec; 44(12):1755-61. PubMed ID: 15584991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation.
    Díaz MA; Sevilla J; de la Rubia J; Verdeguer A; Espigado I; Vicent MG; Pascual MJ; Zamora C; Arrieta R; Serrano D; del Cañizo C; Arbona C; de Arriba F; Bargay J; Brunet S; Sanz MA
    Haematologica; 2003 Aug; 88(8):919-22. PubMed ID: 12935980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors.
    Martínez C; Urbano-Ispizua A; Marín P; Merino A; Rovira M; Carreras E; Montserrat E
    Bone Marrow Transplant; 1999 Dec; 24(12):1273-8. PubMed ID: 10627634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes and graft characteristics in pediatric matched sibling donor transplants using granulocyte colony-stimulating factor-primed bone marrow and steady-state bone marrow.
    Chiang KY; Haight A; Horan J; Olson E; Gartner A; Hartman D; Youssef S; Worthington-White D
    Pediatr Transplant; 2007 May; 11(3):279-85. PubMed ID: 17430483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive factors that affect the mobilization of CD34(+) cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF).
    Martino M; Callea I; Condemi A; Dattola A; Irrera G; Marcuccio D; Messina G; Pontari A; Pucci G; Console G; Lacopino P
    J Clin Apher; 2006 Oct; 21(3):169-75. PubMed ID: 16532489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Administration of erythopoietin and granulocyte colony-stimulating factor in donor/recipient pairs to collect peripheral blood progenitor cells (PBPC) and red blood cell units for use in the recipient after allogeneic PBPC transplantation.
    Sautois B; Baudoux E; Salmon JP; Michaux S; Schaaf-Lafontaine N; Pereira M; Paulus JM; Fillet G; Beguin Y
    Haematologica; 2001 Nov; 86(11):1209-18. PubMed ID: 11694408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease.
    Rosenbaum C; Peace D; Rich E; Van Besien K
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):719-23. PubMed ID: 18489998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effect of matrix metalloproteinase-9 in granulocyte colony stimulation factor-induced stem cell mobilization].
    Jin FY; Qiu LG; Li QC; Meng HX; Wang YF; Yu Z; Li Q; Han JL
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(42):2966-70. PubMed ID: 17288807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Harvesting peripheral blood stem cells from healthy donors on 4th day of cytokine mobilization.
    Sohn SK; Kim JG; Sung WJ; Kim DH; Suh JS; Lee KS; Lee KB
    J Clin Apher; 2003; 18(4):186-9. PubMed ID: 14699595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors.
    Pulsipher MA; Nagler A; Iannone R; Nelson RM
    Pediatr Blood Cancer; 2006 Apr; 46(4):422-33. PubMed ID: 16411207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
    Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
    Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mobilization of autologous peripheral blood stem cells by chemotherapy and recombinant granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF)].
    Cui X; Shao Y; Ren B; Tong Z; Ren X; Li L; Zhang Z; Zhang N; Dai R; Hao X
    Zhonghua Xue Ye Xue Za Zhi; 2000 May; 21(5):247-9. PubMed ID: 11876989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
    Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythema exsudativum multiforme induced by granulocyte colony-stimulating factor in an allogeneic peripheral blood stem cell donor.
    Mori T; Sato N; Watanabe R; Okamoto S; Ikeda Y
    Bone Marrow Transplant; 2000 Jul; 26(2):239-40. PubMed ID: 10918440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etoposide 1.0 g/m2 or 1.5 g/m2 combined with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells in patients with malignancy: efficacy and toxicity.
    Li B; Yang JL; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang S; Zhang CG
    Cytotherapy; 2009; 11(3):362-71. PubMed ID: 19037766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor.
    Cavallaro AM; Lilleby K; Majolino I; Storb R; Appelbaum FR; Rowley SD; Bensinger WI
    Bone Marrow Transplant; 2000 Jan; 25(1):85-9. PubMed ID: 10654020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Granulocyte colony-stimulating factor mobilizes more dendritic cell subsets than granulocyte-macrophage colony-stimulating factor with no polarization of dendritic cell subsets in normal donors.
    Shaughnessy PJ; Bachier C; Lemaistre CF; Akay C; Pollock BH; Gazitt Y
    Stem Cells; 2006 Jul; 24(7):1789-97. PubMed ID: 16822885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of peripheral blood stem cell mobilization and collection: a single-center experience in 190 allogeneic donors.
    Rinaldi C; Savignano C; Pasca S; Sperotto A; Patriarca F; Isola M; Fanin R; De Angelis V
    Transfusion; 2012 Nov; 52(11):2387-94. PubMed ID: 22452363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.